8 June 2022

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Result of AGM

Ondine Biomedical Inc. (AIM: OBI) announces that at its Annual General Meeting held on 7 June 2022 all resolutions were duly passed.

**ENDS**

About Ondine Biomedical Inc.

Ondine Biomedical Inc. (AIM: OBI) is a Canadian headquartered, medical device company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens' cell membranes and surface proteins through an oxidative burst without impact on human tissue. 

Ondine has a pipeline of products, based on its patent protected photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonisation of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the U.S. by the FDA.

For more information, please visit:  www.ondinebio.com or contact: